Delving into the Latest Updates on Tibet Huaxi Pharmaceuticals Group Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Congenital Disorders

Eye Diseases

Chemical drugs

Small molecule drug

Interleukins

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Infectious Diseases	2
Immune System Diseases	1

Top 5 Drug Type	Count

Chemical drugs	4
Small molecule drug	2
Antibody	1
Interleukins	1

Top 5 Target	Count

VEGF(Vascular endothelial growth factor)	1
IL1R1(Interleukin-1 receptor)	1
LANCL2(LanC like 2)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

2

Phase 1 Clinical

Phase 2 Clinical

1

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Hematoporphyrin	Neoplasms More	Approved
Recombinant human interleukin-1 receptor antagonist(Tibet Huaxi Pharmaceuticals) ( IL1R1 )	Blepharokeratoconjunctivitis More	Phase 2
ML-PHOTOXNEO01	Esophageal Carcinoma More	Phase 1
ML-CA-06 ( VEGF )	Neoplasms More	Phase 1
ML-PHOTOXPH03	Myopia More	Preclinical